Derin

Quick links to important sections

Derin

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Derin

Property Description
Active ingredient Quetiapine (Quetiapine fumarate)
Form Tablet (Immediate-release, Extended-release)
Pharmacological class Atypical Antipsychotic (Second-Generation Antipsychotic)
Origin Synthetic compound

Derin is the trade name for a potent, synthetic pharmaceutical product whose active substance is Quetiapine, often administered as Quetiapine fumarate. It is designated as a prescription-only medicine and is primarily classified as an atypical antipsychotic (APA), placing it among the Second-Generation Antipsychotics (SGAs). The product is manufactured and distributed under the brand name Derin in specific markets, but its active component, Quetiapine, is universally recognized as a core psychotropic agent used to influence mental function.

What is Its Pharmacological Identity?

The identity of Derin is defined by its role as a Second-Generation Antipsychotic, a class supported by pharmacological studies demonstrating a nuanced approach to neurological intervention. Quetiapine distinguishes itself within this class by its dual-action as an antagonist at both the serotonin (5HT2A) and dopamine (D2) receptors. This balanced mechanism is a defining, authoritative feature of its efficacy.

Composition, Origin, and Physical Form

Quetiapine is a single-ingredient product derived from a synthetic chemical process. It is administered via the oral route, most commonly as a film-coated tablet. A key practical feature is the availability of two formats: the standard immediate-release tablet and the engineered extended-release formulation, designed to provide a sustained delivery of the active substance over a prolonged duration. The composition includes the active Quetiapine along with necessary solid pharmaceutical excipients for tablet formation and reliable absorption.

The General Purpose of Atypical Antipsychotics

The fundamental purpose of Quetiapine is to facilitate the restoration of stable function in the central nervous system. By modulating the activity of chemical messengers in the brain through receptor antagonism, the medication’s function is to help stabilize severely disturbed thought processes, moods, and perceptions. This action establishes a necessary chemical equilibrium that provides the therapeutic foundation for managing profound mental dysregulation.

Regulatory References

  1. Quetiapine: MedlinePlus Drug Information

What side effects are possible with Derin?

The safety profile for Derin is established through regulatory review of clinical trial data and post-marketing surveillance reports, categorized by frequency and System-Organ Class (SOC) as per official guidelines from authorities such as the FDA and EMA.

Adverse Reactions and Safety Profile

The most commonly reported adverse reactions documented in regulatory filings are typically mild and often involve the Nervous System and Gastrointestinal System. However, the official documentation explicitly defines categories for reactions based on incidence:

  • Very Common (e.g., incidence ge 1/10): This frequency grouping generally includes reactions such as fatigue, headache, or mild gastrointestinal upset.
  • Common (e.g., incidence ge 1/100 to < 1/10): This category often includes side effects like nausea, rash, or nervous system issues such as dizziness or mild cognitive changes.

Serious and Clinically Significant Risks

The official labeling includes a Warnings and Precautions section detailing risks that are clinically significant. These may include, but are not limited to, the potential for serious cutaneous adverse reactions (SCARs), such as Stevens-Johnson Syndrome, and neuropsychiatric events, including agitation or suicidal ideation. Specific attention is given to:

  • Population-Specific Concerns: Safety data highlights the need for particular caution in certain groups, such as patients with pre-existing renal or hepatic impairment, often necessitating careful monitoring.
  • Dose- or Exposure-Related Patterns: The risk and severity of certain serious adverse effects may be noted as being influenced by the dose administered or the duration of use, requiring adherence to prescribed limitations.

Regulatory Limitations and Monitoring

Contraindications are formally defined to specify conditions or patient populations for whom the use of Derin is strictly prohibited due to unacceptable risk. Furthermore, the official prescribing information mandates high-level safety monitoring, requiring healthcare providers to check specific laboratory and functional parameters periodically throughout treatment to mitigate potential risks and ensure appropriate management of the safety profile.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Derin (Quetiapine) may lead to severe manifestations primarily affecting the Central Nervous System and Cardiovascular System, requiring immediate medical intervention as mandated by regulatory authorities.

Domain Official Regulatory Statement
Documented Manifestations Symptoms include profound somnolence, severe sedation, tachycardia, and hypotension [FDA Label Quetiapine Fumarate - Section 10]. Delirium and anticholinergic effects like urinary retention are also documented [EMA SmPC Quetiapine - Section 4.9].
Severe Outcomes Risk of progression to coma, seizures, respiratory depression, and potential death (especially with mixed ingestion). QTc prolongation is a documented risk requiring continuous ECG monitoring [FDA Label Quetiapine Fumarate - Section 10].
Emergency Actions Seek immediate medical attention and contact emergency services (e.g., Poison Control) for any suspected overdose [NIH MedlinePlus Drug Information - Quetiapine]. Hospital admission for continuous monitoring is typically required [EMA SmPC Quetiapine - Section 4.9].
Supportive Care No specific antidote is known [FDA Label Quetiapine Fumarate - Section 10]. Management is symptomatic and supportive, including ensuring a patent airway and considering the use of activated charcoal if administered promptly. Hypotension may require intravenous fluids [EMA SmPC Quetiapine - Section 4.9].
Specific Notes The extended-release (XR) formulation may lead to delayed symptom onset and prolonged effects, necessitating an extended observation period. Elderly patients may show reduced clearance, which could increase sensitivity to overdose effects [Health Canada Product Monograph - Section 10].

The official regulatory documents define the overdose profile by listing the expected manifestations in the central nervous and cardiovascular systems, specifying that symptoms can escalate to life-threatening outcomes. This documented severity directly triggers the mandatory regulatory instruction to seek immediate medical attention and defines the necessary supportive and monitoring procedures required in a hospital setting.

Therapeutic Uses of Derin

What Derin Treats: Main Uses and Benefits

The medication is commonly used to help with symptoms that interfere with daily functioning, specifically across domains involving significant discomfort or tension.

The medication is used for symptomatic relief in conditions such as Schizophrenia, Bipolar Disorder (including acute mania, bipolar depression, and maintenance), and as an adjunct therapy for Major Depressive Disorder (MDD).

It is commonly used across conditions characterized by periods of heightened symptoms and applied in addressing symptom clusters that may become intense or disruptive, such as hallucinations, delusions, and severe mood swings.

“It is considered relevant in contexts marked by increased discomfort or tension, and may assist with coping more steadily with symptom fluctuations.”

This application is relevant in clinical settings that involve acute or unstable symptom patterns. It provides support that helps ease the overall symptom load and contributes to improved comfort during periods of heightened distress.

Quick Note: Symptom Management Context
Derin is often used during phases when symptoms become more noticeable, especially for acute manic episodes and severe bipolar depression, assisting the patient in managing distress and helping with maintaining functional stability.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility for Derin Use: Official Regulatory Status

Derin (Quetiapine) is subject to strict eligibility rules established by regulatory authorities.

Populations for Whom Use is Contraindicated

Classification Restricted Population/Condition
Absolute Exclusion Elderly patients with dementia-related psychosis, due to the increased risk of death associated with atypical antipsychotics [1.3, 1.4].
Absolute Exclusion Individuals with known hypersensitivity to quetiapine or any formulation component [1.3].
Absolute Exclusion Concomitant use with strong CYP3A4 inhibitors (e.g., azole-antifungal agents, HIV-protease inhibitors) [1.2].

Age-Related Eligibility

  • Adults (18+): Approved for all established indications.
  • Adolescents (13–17): Approved for Schizophrenia.
  • Children (10–17): Approved for Bipolar Mania.
  • Pediatric Limitations: Use is not established for Schizophrenia in children under 13 or Bipolar Mania in children under 10. The medicine is not generally recommended for use in individuals under 18 in certain regions [1.2].
  • Geriatric Patients: Official labeling requires the consideration of a lower starting dose and slower titration for older adults [1.3].

Conditional Eligibility

  • Hepatic Impairment: Use must be with caution; a lower initial dose is required due to the liver's role in metabolism [1.2].
  • Pregnancy: Use is conditional: it should only be used if the potential benefit justifies the potential risk [1.6]. Exposure in the third trimester may cause temporary symptoms in the newborn [1.1].
  • Lactation: Official documents advise a decision must be made to discontinue either breastfeeding or the therapy [1.1, 1.6].

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile of Derin (Apixaban/Rivaroxaban) primarily through two critical pathways: the combination of Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) for pharmacokinetic interactions, and agents that affect hemostasis for pharmacodynamic interactions.

Pharmacokinetic Interactions

Derin is a substrate for both CYP3A4 and P-gp. Clinically significant interactions occur when it is co-administered with medicinal products that are strong combined inducers or inhibitors of both pathways.

  • Strong Combined Inducers (e.g., Rifampin, Phenytoin, St. John's Wort): Co-administration must be avoided as it substantially reduces the drug’s concentration, increasing the risk of thromboembolic events.
  • Strong Combined Inhibitors (e.g., Ketoconazole, Itraconazole, Ritonavir): Co-administration is generally avoided or requires a dose reduction, as it increases the drug's concentration and the risk of bleeding. Specific patient criteria (e.g., renal function, existing dose) govern the required restriction.

Pharmacodynamic Interactions

The risk of bleeding is increased when Derin is used concomitantly with other medicinal products that also affect blood clotting or platelet function. This includes other anticoagulants (e.g., Warfarin, Heparin), antiplatelet agents (e.g., Aspirin, Clopidogrel), and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Use with these agents requires clinical monitoring or, for other full-dose anticoagulants, avoidance due to the additive bleeding risk.

Mechanism of Action

How Derin Works

Derin is a small molecule that modulates key signaling pathways to exert its biological and physiological effects. It primarily acts on enzyme-mediated regulatory systems and influences specific receptor signaling to modulate pathways associated with heightened physiological responses.


Enzyme-Mediated Pathway Modulation

Derin functions as an inhibitor within domains involving key intracellular enzymes, such as phosphodiesterases (PDEs). By suppressing the activity of these enzymes, the drug prevents the breakdown of second messengers like cyclic AMP (cAMP), thereby increasing their intracellular concentration. This results in the suppression of processes driven by excessive mediator activity, influencing the cellular regulatory feedback loop.


Receptor-Targeted Signaling Engagement

The drug also engages mechanisms that influence specific receptor-mediated signaling pathways, such as those involving adenosine receptors. By modulating the uptake or action of endogenous mediators like adenosine, Derin modifies early molecular steps that shape systemic physiological outcomes. This activity supports the regulation of processes driven by distinct signaling patterns, results in reduced signaling output within the targeted biological systems.

Dosage and Administration Information

The use of Derin (Quetiapine) involves specific parameters for administration, dosing, and frequency. It is available as an immediate-release (IR) tablet and an extended-release (XR) tablet.

Official Administration Guidelines

Administration Detail Immediate-Release (IR) Tablet Extended-Release (XR) Tablet
Route of Administration Oral (by mouth) Oral (by mouth)
Frequency Typically divided into two to three times daily doses. Administered once daily
With/Without Food May be taken with or without food. Should be taken without food or with a light meal.
Tablet Integrity (No specific restriction stated) Must be swallowed whole; do not split, chew, or crush.

Standard Dosing and Time Course

Treatment initiation is characterized by a gradual dose increase (titration) over the first few days to reach the target dose range. For instance, in adults, the daily dosage for acute manic episodes is titrated from 100 mg on Day 1 up to 400 mg by Day 4.

Maintenance dosing varies by condition:

  • Schizophrenia and Acute Bipolar Mania: Recommended maintenance ranges generally from 400 mg to 800 mg per day. The maximum dose is 750 mg for IR tablets and 800 mg for XR tablets.
  • Bipolar Depression: The target and maximum dose is 300 mg per day, typically administered once daily at bedtime.

For specific populations, modifications are utilized: older adult patients and those with hepatic impairment require a lower starting dose (e.g., 25 mg or 50 mg per day) and a slower rate of dose escalation. Upon treatment cessation, a gradual dose reduction over at least one to two weeks is employed.

Recent Clinical Evidence

Derin: Recent Clinical Evidence

This overview summarizes the official research evidence for Derin (Quetiapine), focusing on the types of studies conducted, the outcomes they measured, and what remains unclear in the research landscape. It is strictly a non-advisory summary of scientific literature and regulatory findings.

Evidence for Use in Schizophrenia

Research exploring short-term symptom changes in Schizophrenia was conducted through randomized, controlled clinical trials (RCTs), typically lasting 4 to 6 weeks. These studies examined outcomes related to episodic or acute changes in psychotic symptoms. Long-term maintenance studies were also conducted, sometimes for up to a year, to assess durability and monitor the time elapsed before symptom recurrence. The existing research provides limited information for long-term outcomes regarding the return to daily functioning or overall quality of life.


Evidence for Use in Bipolar Disorder

Studies focused on episodes where symptoms become more noticeable were conducted using short-term RCTs (3 to 12 weeks) for acute mania and approximately 8 weeks for acute depression. The medicine was explored as monotherapy or as an addition (adjunctive therapy). The long-term evidence comes from maintenance RCTs that followed patients for up to two years to monitor the time elapsed until the recurrence of a mood event. Comparative evidence against all possible competing treatments is still an area where data are limited.


Evidence in Special Populations and Uncertainties

Research has been conducted in certain younger populations, including adolescents (aged 13–17 years) with Schizophrenia and children and adolescents (aged 10–17 years) with Bipolar Disorder. For older adults, certainty regarding long-term, specific use remains low compared to the core adult populations. A persistent limitation is the limited information for long-term outcomes that reflect daily functioning outside the measured symptom scales. Additionally, data for certain groups remain insufficient, especially when considering long-term effects.

Frequently Asked Questions (FAQ)

Common questions about Derin (FAQ)

Q: What is Derin used for besides the main condition?

A: Regulatory documents state that Derin (Quetiapine) is officially indicated for the treatment of Schizophrenia and episodes associated with Bipolar Disorder, including both manic and depressive episodes. Additionally, the extended-release formulation is approved in some regions to be used alongside other antidepressants for Major Depressive Disorder (MDD). These are the main conditions that the medicine has been approved to address.


Q: Is Derin a type of painkiller?

A: The official classification for the active ingredient in Derin (Quetiapine) is an atypical antipsychotic, placing it in a class of medicines used to influence mental function. The product is not indicated for the management or relief of pain.


Q: How quickly does Derin start to work after the first dose?

A: The onset of the medicine's full effect is variable among individuals and is thought to be related to the gradual dose increase, known as titration, that occurs over the first few days of treatment. In clinical trials, symptom improvement has typically been measured over a course of several weeks.


Q: What is the average time before Derin reaches its full effect?

A: Studies and official information indicate that the full therapeutic benefit is generally observed over the course of the first several weeks of treatment. Clinical trials that assessed the full effect for acute symptoms typically lasted between 3 to 6 weeks.


Q: How long does Derin stay in your system?

A: The mean terminal elimination half-life for Derin’s active ingredient (Quetiapine) is approximately 7 hours. The extended-release (XR) formulation, however, is specifically designed to provide a sustained delivery of the medicine over a 24-hour period.


Q: Does Derin change how other medicines are absorbed?

A: Official product information notes that the medicine is a substrate for P-glycoprotein (P-gp), which is a system in the body that plays a role in how medicines are transported in and out of cells. This indicates that Derin is processed by and potentially affects these transportation systems.


Q: Can Derin be taken with over-the-counter cold and flu medicine?

A: Official warnings caution against combining this medicine with other agents that cause Central Nervous System (CNS) depression, such as some cold and flu products, due to the risk of increased side effects like sleepiness. Official documents also caution regarding use with sympathomimetic agents, which may be found in certain OTC products.


Q: Are there any specific vitamins or supplements that interact with Derin?

A: Official regulatory information advises against the co-administration of the medicine with the supplement St. John’s Wort. This supplement is classified as a strong inducer of the CYP3A4 pathway, which can potentially affect the blood levels of Derin.


Q: Is it okay to take Derin if I occasionally drink alcohol?

A: Official patient counseling information cautions against the consumption of alcohol while taking this medicine, as alcohol may increase drowsiness or other nervous system side effects.


Q: Why do some people report feeling tired when they start taking Derin?

A: Sleepiness, or somnolence, is a very common adverse reaction listed in official documents. This effect is thought to be related to the medicine’s activity in the brain, including its known effect of blocking certain receptors, such as histamine H1 receptors.


Q: Is Derin known to cause weight gain or loss?

A: The official labeling classifies weight gain as a common adverse reaction and notes that this is part of a metabolic change that requires periodic safety monitoring. Weight changes are a possible effect noted in the official product information.


Q: Does Derin affect sleep patterns?

A: Official documentation lists sleepiness, or somnolence, as a very common adverse reaction. The product is also noted in some documents as having sleep-promoting effects, which means it can influence periods of rest.


Q: Is Derin considered safe for long-term use?

A: Official regulatory documents confirm that long-term maintenance studies have been conducted for up to two years to evaluate the medicine’s durability. However, the existing research provides limited information for long-term outcomes regarding the return to daily functioning or overall quality of life.


Q: If I miss a dose of Derin, what should I generally do?

A: Official patient counseling information generally addresses this scenario by stating that a missed dose should be taken as soon as it is remembered, unless it is nearly time for the next scheduled dose. If it is almost time for the next dose, the missed dose should be skipped.


Q: What is the difference between Derin and other drugs in the same class?

A: The official identity of Derin (Quetiapine) is characterized by its balanced action as an antagonist at both the serotonin (5 HT2 A) and dopamine ( D2) receptors in the brain. This dual-action mechanism is an authoritative feature that helps distinguish its profile within its pharmacological class.


Q: Can Derin cause blurred vision?

A: Blurred vision is listed as a reported adverse reaction in the official labeling.


Q: Can people with kidney issues use Derin?

A: Official documentation states that caution and careful monitoring are needed for patients with pre-existing renal (kidney) impairment, but its use is not absolutely prohibited for this population.


Q: Can taking Derin affect the results of blood tests?

A: Yes, the official documentation requires periodic monitoring of specific laboratory parameters throughout the course of treatment. These checks often include monitoring for metabolic changes, such as blood sugar and lipid levels, and blood cell counts.


Q: Is Derin used to treat anxiety or depression?

A: Derin is officially indicated for treating depressive episodes associated with Bipolar Disorder and is also approved for adjunctive treatment of Major Depressive Disorder (MDD). Official regulatory documents do not list general anxiety as an approved indication.


Q: How often should someone get check-ups while on Derin?

A: Official regulatory guidelines mandate periodic safety monitoring throughout treatment. While the exact frequency may vary, the required checks for key metabolic parameters (such as blood sugar and lipids) are often described in guidelines as occurring at least annually following initial baseline tests.


Q: Is it true that grapefruit juice can interact with Derin?

A: Yes, the official product information cautions against the consumption of grapefruit or grapefruit juice while taking this medicine. Grapefruit can increase the amount of Derin in the blood, potentially leading to increased effects.


Q: Why are there warnings about driving or operating machinery while taking Derin?

A: The official documentation includes a warning about the potential for cognitive and motor impairment while using this medicine, due to side effects like drowsiness or dizziness.


Q: How does Derin affect blood pressure?

A: Official labeling warns of the potential for hypotension (low blood pressure), especially orthostatic hypotension, which can cause dizziness when standing up. Additionally, increases in blood pressure have been noted to occur in children and adolescents.


Q: If someone is allergic to penicillin, can they still take Derin?

A: Official documentation specifies that the product is contraindicated only for those with known hypersensitivity to quetiapine or any component of the formulation itself. The regulatory labeling does not provide guidance on potential cross-reactivity with other medicine classes like penicillin.


Q: Is there a known 'washout period' if stopping Derin?

A: Official documentation advises against abruptly stopping the medicine and states that gradual dose reduction over at least one to two weeks is required. This is done to manage discontinuation syndrome and helps the body adjust slowly.


Q: Do studies suggest Derin works better for some patient groups than others?

A: Official summaries note that research has been conducted in specific age groups, such as adolescents and older adults. Official documents state that the certainty of long-term data for some special populations remains low compared to the core adult populations.


Q: Is the purpose of Derin a treatment or a cure?

A: Official documentation identifies the product as a prescription medicine used to treat approved conditions. Its function is described as helping to stabilize severely disturbed thought processes, moods, and perceptions. The medicine is not described as a cure for the condition itself.


Q: Does Derin interfere with birth control pills?

A: Official labeling notes that the medicine can lead to hyperprolactinemia (increased prolactin), which can potentially affect reproductive function. However, no specific regulatory advice regarding the efficacy of hormonal contraceptives (birth control pills) is generally provided in the official documentation.


Q: What are the common signs of an overdose with Derin?

A: Signs and symptoms reported in official overdose sections include excessive sedation, dizziness, a fast heartbeat (tachycardia), and low blood pressure (hypotension). Any suspected overdose should be addressed immediately by medical professionals.


Q: Is Derin listed as a controlled substance?

A: Official regulatory documents state that Derin (Quetiapine) is not currently classified as a controlled substance under the federal Controlled Substances Act.

How should Derin be stored and disposed of?

How to Store and Dispose of Derin (Quetiapine Fumarate)

Official regulatory documents require Derin tablets to be stored at controlled room temperature, typically 20 C to 25 C. The product must be protected from excess heat, moisture, and light, and it must be kept from freezing.

To ensure stability, the medication must remain in its original container, which should be kept tightly closed. Do not use the tablets past the expiry date printed on the package.

Crucially, Derin must be stored out of the sight and reach of children, with all safety caps securely locked.

Disposal instructions mandate using an authorized drug take-back program or, if unavailable, following specific household trash steps by mixing the non-crushed tablets with an undesirable substance. The medicine should not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Derin found in:

A-Z Index: